Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03201861 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 31, 2022 to Aug 31, 2027
    • Study completion date: Dec 31, 2022 to Dec 31, 2027
    v8
  2. Primary completion date: May 31, 2021 to Aug 31, 2022
    • Study completion date: Dec 31, 2021 to Dec 31, 2022
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Start date changed from estimate of Apr 10, 2018 to Jul 27, 2017v5
  5. Start date: Dec 19, 2017 to Apr 10, 2018v4
Show 2 earlier versionsHide 2 earlier versions
  1. Phase: Phase 2 to Phase 3
    • Start date: Nov 15, 2017 to Dec 19, 2017
    • Eligibility criteria expanded, about 7 words
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 20, 2017 to Nov 15, 2017
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RenJi Hospital
190 trials monitored
See 2 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer .
Trial Details
NCT Number NCT03201861
Lead Sponsor RenJi Hospital
Conditions
(from sponsor)		 Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast
Related terms Carcinoma, Ductal, Breast
Enrollment 762 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov